Increasing functional cure rates after nucleo(s)tide analogue withdrawal: is peg-IFN the answer?

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2024-10-22 DOI:10.1016/j.jhep.2024.10.019

Edo J. Dongelmans, Milan J. Sonneveld, Harry L.A. Janssen

{"title":"Increasing functional cure rates after nucleo(s)tide analogue withdrawal: is peg-IFN the answer?","authors":"Edo J. Dongelmans, Milan J. Sonneveld, Harry L.A. Janssen","doi":"10.1016/j.jhep.2024.10.019","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Clinical trial number:</h2>not applicable.</section></section><section><section><h2>Conflict of interest:</h2>Edo Dongelmans has no conflicts of interests; Milan Sonneveld receives speakers’ fees and research support from Roche, Bristol Myers Squibb, Gilead Sciences, and Fujirebio. Harry Janssen received grants from: Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc. and is consultant for: Aligos, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc., Precision Biosciences, Griffols.</section></section><section><section><h2>Financial support:</h2>No funding was received for this article.</section></section><section><section><h2>Author contributions:</h2>Edo Dongelmans, MD (Conceptualization: Equal; Writing – original draft: Lead). Milan Sonneveld, MD, PhD (Conceptualization: Equal; Writing – review & editing: Equal). Harry L.A. Janssen, MD, PhD (Conceptualization: Equal; Supervision: Lead; Writing – review & editing: Equal).</section></section><section><section><h2>Data availability statement:</h2>not applicable.Nucleo(s)tide analogues (NA) are well-tolerated and highly effective in suppressing HBV DNA in patients with chronic hepatitis B (CHB). Unfortunately, the risk of HCC may persist, particularly in patients who do not achieve functional cure, defined as loss of HBsAg loss. As functional cure is rarely achieved with NA mono-therapy,<sup>1</sup> alternative strategies are explored to increase HBsAg clearance.Recent trials with novel compounds suggest that immune modulatory agents likely play a</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"115 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.10.019","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Clinical trial number:

not applicable.

Conflict of interest:

Edo Dongelmans has no conflicts of interests; Milan Sonneveld receives speakers’ fees and research support from Roche, Bristol Myers Squibb, Gilead Sciences, and Fujirebio. Harry Janssen received grants from: Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc. and is consultant for: Aligos, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc., Precision Biosciences, Griffols.

Financial support:

No funding was received for this article.

Author contributions:

Edo Dongelmans, MD (Conceptualization: Equal; Writing – original draft: Lead). Milan Sonneveld, MD, PhD (Conceptualization: Equal; Writing – review & editing: Equal). Harry L.A. Janssen, MD, PhD (Conceptualization: Equal; Supervision: Lead; Writing – review & editing: Equal).

Data availability statement:

not applicable.Nucleo(s)tide analogues (NA) are well-tolerated and highly effective in suppressing HBV DNA in patients with chronic hepatitis B (CHB). Unfortunately, the risk of HCC may persist, particularly in patients who do not achieve functional cure, defined as loss of HBsAg loss. As functional cure is rarely achieved with NA mono-therapy,¹ alternative strategies are explored to increase HBsAg clearance.Recent trials with novel compounds suggest that immune modulatory agents likely play a

查看原文本刊更多论文

提高核苷酸类似物停药后的功能性治愈率：peg-IFN 是答案吗？

章节片段临床试验编号：不适用。利益冲突：Edo Dongelmans 没有利益冲突；Milan Sonneveld 从罗氏、百时美施贵宝、吉利德科学公司和 Fujirebio 获得演讲费和研究支持。Harry Janssen 从以下公司获得资助：吉利德科学公司、葛兰素史克公司、杨森公司、罗氏公司、Vir 生物技术公司，并担任以下公司的顾问：作者贡献：Edo Dongelmans，医学博士（构思：Equal；写作-原稿：Lead）。Milan Sonneveld，医学博士（构思：等同；写作 - 审稿 & 编辑：等同）。Harry L.A. Janssen, MD, PhD（构思：等同；指导：等同）：平等；指导：撰写-审核-编辑：相同）：核苷酸类似物（NA）在抑制慢性乙型肝炎（CHB）患者的 HBV DNA 方面耐受性好、疗效高。遗憾的是，HCC 的风险可能持续存在，尤其是在未达到功能性治愈（即 HBsAg 消失）的患者中。由于 NA 单一疗法很少能实现功能性治愈1 ，因此人们开始探索其他策略来提高 HBsAg 清除率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.